News FDA rejects Amgen/UCB osteoporosis drug The FDA has rejected Amgen and UCB’s Evenity (romosozumab) osteoporosis drug after a late-stage trial unexpectedly highlighted a potential cardiac safety risk.
News Safety restrictions spell the end for Servier osteoporosis d... Sales of Protelos hit by safety restrictions.
News Amgen/UCB's osteoporosis drug hit by cardio risk Competitor to Amgen's Epogen also moves closer to market
News Pfizer's fast-tracked leukaemia candidate could rival CAR-Ts Antibody-drug conjugate with FDA gets six-month review.
News Amgen/UCB reveal new osteoporosis drug data But romosozumab missed secondary endpoint of non-vertebral fractures
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.